MD Anderson doubles up on cancer 'Moon Shots'

MD Anderson, which has attracted a who's who in immuno-oncology as partners for its Moon Shots R&D program, is adding 6 new cancers to its list of targets. The research institution is doubling down on its moon shots, adding B-cell lymphomas, glioblastoma, HPV, multiple myeloma, colorectal and pancreatic cancers to the list. "As the Moon Shots Program matures, we're transitioning from the foundational phase to the results phase, and some moon shots already are making practice-changing advances in the clinic and in cancer prevention and control," says MD Anderson's Ronald DePinho. Release

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera